Inhibitory effects of trans-resveratrol analogs molecules on the proliferation and the cell cycle progression of human colon tumoral cells

Authors

  • Anna-Kristina Marel,

    1. INSERM U866, Dijon, France. Fax: +33-3-80-39-62-50
    2. Centre de Recherche-Biochimie Métabolique et Nutritionnelle (LBMN), Faculté des Sciences Gabriel, Université de Bourgogne, Dijon, France
    Search for more papers by this author
  • Gérard Lizard,

    1. INSERM U866, Dijon, France. Fax: +33-3-80-39-62-50
    2. Centre de Recherche-Biochimie Métabolique et Nutritionnelle (LBMN), Faculté des Sciences Gabriel, Université de Bourgogne, Dijon, France
    Search for more papers by this author
  • Jean-Claude Izard,

    1. Actichem, 121 boulevard du Danemark, Montauban, France
    Search for more papers by this author
  • Norbert Latruffe,

    1. INSERM U866, Dijon, France. Fax: +33-3-80-39-62-50
    2. Centre de Recherche-Biochimie Métabolique et Nutritionnelle (LBMN), Faculté des Sciences Gabriel, Université de Bourgogne, Dijon, France
    Search for more papers by this author
  • Dominique Delmas

    1. Centre de Recherche-Biochimie Métabolique et Nutritionnelle (LBMN), Faculté des Sciences Gabriel, Université de Bourgogne, Dijon, France
    Search for more papers by this author

Abstract

Resveratrol may function as a cancer chemopreventive agent. However, few data are available on the antitumoral activities of its dimer, ε-viniferin, also present in human diet. So, the effects of resveratrol, ε-viniferin, of their acetylated forms (resveratrol triacetate, ε-viniferin pentaacetate) and of vineatrol (a wine grape extract) were compared on human adenocarcinoma colon cells. Resveratrol and resveratrol triacetate inhibit cell proliferation and arrest cell cycle. ε-Viniferin and ε-viniferin pentaacetate slightly reduce cell proliferation. Vineatrol inhibits cell proliferation and favors an accumulation in the S phase of the cell cycle. Consequently, resveratrol triacetate and vineatrol could constitute new putative anticancer agents on colon carcinoma.

Ancillary